Jim Simons Lian Bio Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.6 $84,319 - $291,630	63,398 Added 22.43%	346,000 $1.55 Million
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.46 $38,588 - $63,709	-25,898 Reduced 8.39%	282,602 $421,000
Q2 2023 Aug 11, 2023	BUY	$1.79 - $2.85 $22,017 - $35,055	12,300 Added 4.15%	308,500 $703,000
Q1 2023 May 12, 2023	BUY	$1.57 - $2.66 $8,757 - $14,837	5,578 Added 1.92%	296,200 $581,000
Q4 2022 Feb 13, 2023	SELL	$1.14 - $2.11 $27,790 - $51,437	-24,378 Reduced 7.74%	290,622 $477,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $475,167 - $762,300	254,100 Added 417.24%	315,000 $630,000
Q2 2022 Aug 12, 2022	BUY	$2.15 - $6.01 $52,408 - $146,499	24,376 Added 66.74%	60,900 $132,000
Q1 2022 May 13, 2022	BUY	$2.8 - $6.21 $102,267 - $226,814	36,524 New	36,524 $136,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.